Disc Medicine Inc
IRON79.720USD
+1.390+1.77%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
2.79BValor de mercado
PerdaP/L TTM
Mais detalhes de Disc Medicine Inc Empresa
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Informações de Disc Medicine Inc
Código da empresaIRON
Nome da EmpresaDisc Medicine Inc
Data de listagemAug 12, 2020
CEOQuisel (John D)
Número de funcionários84
Tipo de títulosOrdinary Share
Fim do ano fiscalAug 12
Endereço321 Arsenal Street, Suite 101
CidadeWATERTOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02472
Telefone16176749274
Sitehttps://www.discmedicine.com/
Código da empresaIRON
Data de listagemAug 12, 2020
CEOQuisel (John D)
Executivos da empresa Disc Medicine Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
36.87K
--
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
6.03K
-63499.00%
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Director
Director
--
--
Dr. John D. Quisel, J.D., Ph.D.
Dr. John D. Quisel, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Kevin J. Bitterman, Ph.D.
Mr. Kevin J. Bitterman, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mark Chin
Mr. Mark Chin
Independent Director
Independent Director
--
--
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Independent Director
Independent Director
--
--
Dr. William Savage, M.D., Ph.D.
Dr. William Savage, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
36.87K
--
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
6.03K
-63499.00%
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Director
Director
--
--
Dr. John D. Quisel, J.D., Ph.D.
Dr. John D. Quisel, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Kevin J. Bitterman, Ph.D.
Mr. Kevin J. Bitterman, Ph.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sáb, 31 de jan
Atualizado em: sáb, 31 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
10.43%
Access Industries, Inc.
7.46%
RA Capital Management, LP
5.90%
The Vanguard Group, Inc.
4.67%
BlackRock Institutional Trust Company, N.A.
4.49%
Outro
67.05%
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
10.43%
Access Industries, Inc.
7.46%
RA Capital Management, LP
5.90%
The Vanguard Group, Inc.
4.67%
BlackRock Institutional Trust Company, N.A.
4.49%
Outro
67.05%
Tipos de investidores
Investidores
Proporção
Investment Advisor
40.95%
Investment Advisor/Hedge Fund
19.54%
Hedge Fund
15.71%
Venture Capital
11.72%
Private Equity
8.55%
Corporation
7.46%
Research Firm
2.13%
Sovereign Wealth Fund
0.90%
Individual Investor
0.43%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
358
37.59M
99.56%
-1.45M
2025Q3
341
35.08M
92.93%
-3.22M
2025Q2
344
37.34M
107.82%
+1.72M
2025Q1
342
37.53M
108.38%
+1.77M
2024Q4
318
30.70M
90.70%
-5.11M
2024Q3
302
32.06M
106.93%
-4.30M
2024Q2
292
32.17M
107.84%
+2.52M
2024Q1
275
26.60M
108.28%
-1.06M
2023Q4
248
24.37M
101.48%
-1.80M
2023Q3
211
23.78M
99.79%
-259.52K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Fidelity Management & Research Company LLC
3.94M
10.43%
+855.03K
+27.73%
Sep 30, 2025
Access Industries, Inc.
2.81M
7.46%
-744.05K
-20.91%
Oct 20, 2025
RA Capital Management, LP
1.58M
4.18%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
1.44M
3.82%
+51.32K
+3.69%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
1.70M
4.49%
-17.33K
-1.01%
Sep 30, 2025
Atlas Venture
1.51M
4.01%
-628.74K
-29.34%
Dec 17, 2025
Frazier Life Sciences Management, L.P.
1.44M
3.81%
-216.30K
-13.07%
Sep 30, 2025
OrbiMed Advisors, LLC
1.42M
3.75%
--
--
Sep 30, 2025
Wellington Management Company, LLP
1.41M
3.74%
-22.01K
-1.54%
Sep 30, 2025
T. Rowe Price Associates, Inc.
1.30M
3.44%
-194.10K
-12.99%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
ALPS Medical Breakthroughs ETF
1.25%
Virtus LifeSci Biotech Clinical Trials ETF
1.11%
JPMorgan Healthcare Leaders ETF
0.92%
State Street SPDR S&P Biotech ETF
0.79%
Direxion Daily S&P Biotech Bull 3X Shares
0.48%
JPMorgan Fundamental Data Science Small Core ETF
0.4%
ProShares Ultra Nasdaq Biotechnology
0.39%
Invesco Nasdaq Biotechnology ETF
0.29%
iShares Health Innovation Active ETF
0.27%
iShares Biotechnology ETF
0.18%
Ver Mais
ALPS Medical Breakthroughs ETF
Proporção1.25%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção1.11%
JPMorgan Healthcare Leaders ETF
Proporção0.92%
State Street SPDR S&P Biotech ETF
Proporção0.79%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.48%
JPMorgan Fundamental Data Science Small Core ETF
Proporção0.4%
ProShares Ultra Nasdaq Biotechnology
Proporção0.39%
Invesco Nasdaq Biotechnology ETF
Proporção0.29%
iShares Health Innovation Active ETF
Proporção0.27%
iShares Biotechnology ETF
Proporção0.18%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Data
Data ex-dividendo
Tipo
Proporção
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
